The crystal structure of the MDM2-p53 complex revealed that the N-terminal portion of p5315–29 is important in binding to MDM2, and several small-molecule compounds or peptides mimicking the MDM2 binding site of p53 antagonize MDM2 and activate the p53 pathway in cancer cells [12]–[15]. Here, TP53 is linked to cancer.